

Xiaoyu Xu

Associate



xxu@cooley.com

+86 10 8540 0652

Beijing

Capital Markets Venture Capital

Mergers and Acquisitions

Life Sciences

Asia

Xiaoyu Xu focuses her practice in the areas of initial public offerings, venture capital investment, mergers and acquisitions, and general corporate matters.

Xiaoyu is a native Mandarin speaker and is fluent in English.

Representative Matters:

Capital Markets

- Represented Keymed Biosciences in its US\$400 million listing and global offering on the Main Board of the HKEX
- Represented Betta Pharmaceuticals in its proposed listing and global offering on the Main Board of the HKFX
- Represented Keymed Biosciences in its proposed listing and global offering on the Main Board of the HKEX
- Represented Jacobio Pharmaceuticals in its US\$330 million listing and global offering on the Main Board of the HKEX
- Represented RemeGen in its US\$515 million listing and global offering on the Main Board of the HKEX
- Represented Peijia Medical in its US\$348 million listing and global offering on the Main Board of the HKEX
- Represented Fortune Financial Capital in the US\$56.8 million listing and global offering of Zero2IPO
 Holdings on the Main Board of the HKEX
- Represented First Shanghai Capital Limited in the HK\$550 million listing and global offering of Chen Lin Education Group Holdings Limited Board of the HKEX

Venture Capital Investments, Mergers & Acquisitions and Corporate Partnering & Licensing

- Represented InnoRNA in its global strategic collaboration with BeiGene to research and develop mRNA-LNP therapeutics
- Represented Vivo Capital in forming a joint venture, Visirna Therapeutics, with Arrowhead Pharmaceuticals (Nasdaq: ARWAR) and subsequent license agreement for exclusive rights to develop and commercialize four of Arrowhead's investigational RNA interference (RNAi) therapeutics for cardiometabolic diseases in Greater China

- Represented Bertelsmann Asia Investments in its multimillion Series A financing in Tantan Limited
- Represented Sequoia Capital and Gobi Partners in their US\$15 million Series B financing in Cloudwise Technology
- Represented JAFCO Investment in its multimillion Series A financing in EasyPrint; and in its multimillion
 Series B financing in JianShi Technology
- Represented **Demohour** in its multimillion dollar Series A financing from Matrix Partners China
- Represented TTM Technologies Inc. on its US\$550 million sales of mobility business unit consisting of four China manufacturing plants

Education

Columbia University LLM,

University of International Business and Economics LLB,

Admissions & Credentials

New York